Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 91.10, up from a previous target of HKD 87.02 [5][4]. Core Views - The company's revenue for 1H25 reached USD 161 million, representing a year-on-year increase of 33.1%, while net profit surged by 583.6% to USD 14 million. Adjusted net profit also increased by 84.8% to USD 20 million, aligning with prior profit forecasts [1]. - The growth in profit is attributed to robust case growth in the domestic market and sustained high growth in overseas revenue. The delay in the investment in new overseas factories resulted in lower operational costs for 1H25, highlighting the potential for overseas business performance without additional factory investments [1]. - Looking ahead to 2H25, the company expects stable net profit figures due to ongoing case growth domestically and internationally, despite uncertainties in the domestic market and increased costs related to overseas supply chain development and patent improvements [1]. Domestic Business Summary - In 1H25, the domestic market generated USD 90 million in revenue, remaining stable compared to 1H24. The case volume grew by 14% year-on-year to approximately 95,300 cases [2]. - For the full year of 2025, the company anticipates domestic case volume to reach 250,000 cases, driven by the demand for children's orthodontics and product upgrades for adult patients [2]. Overseas Business Summary - The overseas market achieved USD 72 million in revenue for 1H25, marking a 123% year-on-year increase, with case volume rising by 103.5% to 117,200 cases [3]. - The company expects continued high growth in overseas case volume, potentially reaching 240,000 to 250,000 cases for the year, supported by improved product recognition and local sales support structures [3]. Profit Forecast and Valuation - The adjusted EPS forecast for 2025, 2026, and 2027 is USD 0.16, USD 0.16, and USD 0.21 respectively. The company is assigned a 73x PE for 2025, reflecting a premium over comparable companies due to its unique market position and growth potential [4][5]. - The target price of HKD 91.10 reflects the company's growth trajectory and market conditions, with a significant upside from the current closing price of HKD 68.10 [5].